Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Richard Daifuku"'
Publikováno v:
Translational Medicine Communications, Vol 9, Iss 1, Pp 1-14 (2024)
Abstract Background iMN013 (5-aza-2',2'-difluorodeoxycytidine), a DNA methyl transferase inhibitor and ribonucleotide reductase inhibitor, and its prodrug iMN041 (3',5'-di-trimethylsilyl-2',2'-difluro-5- azadeoxycytidine), have been shown to be activ
Externí odkaz:
https://doaj.org/article/bd3d723a34284406b6060a4f5b3e8461
Publikováno v:
Pharmaceuticals, Vol 11, Iss 2, p 36 (2018)
5-aza-2′,2′-difluorodeoxycytidine (NUC013) has been shown to be significantly safer and more effective than decitabine in xenograft models of human leukemia and colon cancer. However, it suffers from a similar short half-life as other DNA methylt
Externí odkaz:
https://doaj.org/article/531acd7e34bc46a7805d8b66d889b61b
Publikováno v:
Pharmaceuticals, Vol 11, Iss 1, p 16 (2018)
Vitamin E phosphate (VEP) nucleoside prodrugs are designed to bypass two mechanisms of tumor resistance to therapeutic nucleosides: nucleoside transport and kinase downregulation. Certain isoforms of vitamin E (VE) have shown activity against solid a
Externí odkaz:
https://doaj.org/article/12fb749276b741f79972a6eb1e682574
Publikováno v:
Pharmaceuticals, Vol 10, Iss 3, p 65 (2017)
Tumor suppressor genes can be silenced genetically as well as epigenetically. One approach to reversing epigenetic suppression of tumor suppressor genes is to inhibit DNA methyl transferase. 5-aza-2′,2′-difluorodeoxycytidine (NUC013) is a novel D
Externí odkaz:
https://doaj.org/article/3c2465de2e0a41dd9db045254d9eb970
BACKGROUND: iMN013 (5-aza-2’,2’-difluorodeoxycytidine), a DNA methyl transferase inhibitor and ribonucleotide reductase inhibitor, and its prodrug iMN041 (3’,5’-di-trimethylsilyl-2’,2’-difluro-5-azadeoxycytidine), have been shown to be ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d98912991660b3c6a05c8c87cfa5482
https://doi.org/10.21203/rs.3.rs-2920943/v1
https://doi.org/10.21203/rs.3.rs-2920943/v1
Autor:
E. Abou Diwan, Jesper B. Andersen, Saeed Aslani, Nieves Baenas, Wanda Baer-Dubowska, Moinak Banerjee, Bernhard T. Baune, Ahlem Belhadj, Vincent L. Biron, Chad Bousman, Ramón Cacabelos, Pablo Cacabelos, Juan C. Carril, P. Castro-Santos, Si Chen, Yuanyuan Cheng, Anusha Chidambaram, Ramesh Kumar Chidambaram, Teresa Cunha-Oliveira, Richard Daifuku, Christos Damaskos, R. Díaz-Peña, Dimitrios Dimitroulis, Yıldız Dincer, Johanna K. DiStefano, Nathan J. Dupper, Dibyendu Dutta, Aseel Eid, Harris A. Eyre, Qian Feng, Luciana L. Ferreira, Gabriel R. Fries, Anna Garmpi, Nikolaos Garmpis, Jérôme Govin, Joaquín Guerra, Lei Guo, Soumeyya Halayem, Meriem Hamza, Antja-Voy Hartley, Rong-Rong He, Christian Michael Hedrich, Zhiying Huang, Qiuju Huang, Eun Seong Hwang, Jiamin Jin, Morris Kostiuk, Olga Kovalchuk, Igor Kovalchuk, Dongying Li, Seah H. Lim, Cameron Lindsay, Bo Liu, Hong-Min Liu, Zhongqiu Liu, Linlin Lu, Tao Lu, Mahdi Mahmoudi, Aleksandra Majchrzak-Celińska, Matthew Martin, Charles E. McKenna, Kunio Miyake, Ridha Mrad, Patricia Munoz-Garrido, R. Nasr, Baitang Ning, Tomomi Noguchi-Yachide, Colm J. O’Rourke, Douglas V.N.P. Oliveira, Paulo J. Oliveira, Binithamol K. Polakkattil, Joao Quevedo, Ramazan Rezaei, Jason R. Richardson, Kathleen Saavedra, Luis A. Salazar, Ana Sanmartín, Letizia Satriano, Corinne Sidler, Tao Su, Babu Swathy, Oscar Teijido, Iván Tellado, William H. Tolleson, Weida Tong, Ravikumar Vilwanathan, Nguyen Quoc Vuong Tran, Serena Valsami, Anika E. Wagner, Richard M. Watanabe, Wenming Xiao, Dianke Yu, Bin Yu, Tomás Zambrano, R. Zeitoun, N.K. Zgheib, Yingsheng Zhou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::303c1977d82b33f9953bc56a733a6315
https://doi.org/10.1016/b978-0-12-813939-4.09991-5
https://doi.org/10.1016/b978-0-12-813939-4.09991-5
Autor:
Richard Daifuku
The most effective DNA methyltransferase (DNMT) inhibitors remain those nucleosides having a 5-azacytosine base, and include the two approved DNMT inhibitors, decitabine and 5-azacytadine, as well as a recently developed nucleoside, 5-aza-2′,2′-d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::699242125357de45d7122aa3ba55289c
https://doi.org/10.1016/b978-0-12-813939-4.00007-3
https://doi.org/10.1016/b978-0-12-813939-4.00007-3
Autor:
Richard Daifuku
Publikováno v:
Proceedings of 3rd International Electronic Conference on Medicinal Chemistry.
VEP nucleosides bypass two mechanisms of tumor resistance: nucleoside transport and kinase downregulation. Isoforms of VE have shown activity against solid and hematologic tumors. Gemcitabine was conjugated at the 5’ position to either δ-tocophero
Autor:
Richard Daifuku
Publikováno v:
Proceedings of 3rd International Electronic Conference on Medicinal Chemistry.
NUC013 (5-aza-2′,2′-difluroro-deoxycytidine) is preclinically safer and more effective than decitabine (Pharmaceuticals 2017, 10, 65). 5-Azacytidines are hydrolyzed at the cytosine’s 6-position, but in vivo, the short half-life is governed by d
Autor:
Jiirgen B. Bulitta, Ping Zhao, James Pratt, Hans Gelderblom, Richard Daifuku, Robert D. Arnold, Axel-R. Hanauske, Ahmad Awada, Dean R. Kessler, William J. Jusko, Gabriel Luciano
Publikováno v:
Cancer Chemotherapy and Pharmacology. 63:1035-1048
Our objective was to build a mechanism-based pharmacodynamic model for the time course of neutropenia in cancer patients following paclitaxel treatment with a tocopherol-based Cremophor-free formulation (Tocosol Paclitaxel) and Cremophor EL-formulate